Hologic (HOLX) Stock Forecast, Price Target & Predictions
HOLX Stock Forecast
Hologic stock forecast is as follows: an average price target of $80.21 (represents a 1.80% upside from HOLX’s last price of $78.79) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
HOLX Price Target
The average price target for Hologic (HOLX) is $80.21 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $95.00 to $33.00. This represents a potential 1.80% upside from HOLX's last price of $78.79.
HOLX Analyst Ratings
According to 16 Wall Street analysts, Hologic's rating consensus is 'Buy'. The analyst rating breakdown for HOLX stock is 0 'Strong Buy' (0.00%), 11 'Buy' (68.75%), 5 'Hold' (31.25%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Hologic Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | Anthony Petrone | Mizuho Securities | $87.00 | $78.80 | 10.41% | 10.42% |
| Oct 04, 2024 | Anthony Petrone | Mizuho Securities | $90.00 | $79.63 | 13.02% | 14.23% |
| Oct 01, 2024 | Patrick Donnelly | Citigroup | $85.00 | $81.46 | 4.35% | 7.88% |
| Jul 30, 2024 | Mike Matson | Needham | $90.00 | $80.84 | 11.33% | 14.23% |
| Jul 02, 2024 | Vijay Kumar | Evercore ISI | $76.00 | $74.10 | 2.56% | -3.54% |
| Jun 27, 2024 | Ian Zaffino | Oppenheimer | $33.00 | $73.06 | -54.83% | -58.12% |
| May 09, 2024 | David Toung | Argus Research | $95.00 | $75.86 | 25.23% | 20.57% |
| Feb 02, 2023 | - | Cowen & Co. | $95.00 | $83.77 | 13.41% | 20.57% |
| Jan 10, 2023 | - | Wells Fargo | $80.00 | $81.07 | -1.32% | 1.54% |
| Dec 07, 2022 | - | RBC Capital | $75.00 | $74.22 | 1.05% | -4.81% |
The latest Hologic stock forecast, released on Nov 05, 2024 by Anthony Petrone from Mizuho Securities, set a price target of $87.00, which represents a 10.41% increase from the stock price at the time of the forecast ($78.80), and a 10.42% increase from HOLX last price ($78.79).
Hologic Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 7 |
| Avg Price Target | $87.00 | $87.33 | $79.43 |
| Last Closing Price | $78.79 | $78.79 | $78.79 |
| Upside/Downside | 10.42% | 10.84% | 0.81% |
In the current month, the average price target of Hologic stock is $87.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 10.42% increase as opposed to Hologic's last price of $78.79. This month's average price target is down -0.38% compared to last quarter, and up 9.53% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | Needham | Buy | Buy | Hold |
| Oct 14, 2024 | William Blair | Cautious | Cautious | Hold |
| Oct 04, 2024 | Stephens | Sector Perform | Sector Perform | Hold |
| Oct 01, 2024 | Evercore ISI | Positive | Positive | Hold |
| Oct 01, 2024 | Citigroup | Buy | Neutral | Downgrade |
| Sep 17, 2024 | Needham | Buy | Buy | Hold |
| Jul 30, 2024 | Needham | Buy | Buy | Hold |
| Jul 30, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 30, 2024 | Keefe, Bruyette & Woods | Overweight | Overweight | Hold |
| Jul 30, 2024 | RBC Capital | Buy | Buy | Hold |
Hologic's last stock rating was published by Needham on Oct 14, 2024. The company gave HOLX a "Buy" rating, the same as its previous rate.
Hologic Financial Forecast
Hologic Revenue Forecast
| Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $277.90M | $945.30M | $984.40M | $1.03B | $1.07B | $953.30M | $1.00B | $1.44B | $1.47B | $1.32B | $1.17B | $1.54B | $1.61B | $1.35B | $822.90M |
| Avg Forecast | $1.14B | $1.16B | $1.14B | $1.13B | $1.10B | $1.12B | $1.10B | $1.09B | $1.05B | $1.06B | $1.04B | $1.03B | $978.26M | $1.00B | $1.00B | $989.32M | $940.00M | $960.25M | $956.44M | $1.00B | $862.09M | $903.31M | $1.29B | $1.19B | $1.04B | $1.04B | $1.54B | $1.40B | $1.12B | $616.70M |
| High Forecast | $1.15B | $1.18B | $1.15B | $1.14B | $1.11B | $1.13B | $1.11B | $1.10B | $1.06B | $1.07B | $1.06B | $1.04B | $978.71M | $1.00B | $1.00B | $1.02B | $951.96M | $971.03M | $967.18M | $1.02B | $862.09M | $903.31M | $1.29B | $1.19B | $1.04B | $1.04B | $1.54B | $1.40B | $1.12B | $616.70M |
| Low Forecast | $1.14B | $1.16B | $1.13B | $1.12B | $1.10B | $1.11B | $1.09B | $1.09B | $1.05B | $1.05B | $1.04B | $1.03B | $977.81M | $1.00B | $1.00B | $976.49M | $927.37M | $955.80M | $952.01M | $1.00B | $862.09M | $903.31M | $1.29B | $1.19B | $1.04B | $1.04B | $1.54B | $1.40B | $1.12B | $616.70M |
| # Analysts | 4 | 4 | 6 | 5 | 4 | 8 | 5 | 3 | 3 | 6 | 9 | 8 | 4 | 3 | 3 | 6 | 14 | 12 | 7 | 6 | 6 | 7 | 6 | 7 | 10 | 7 | 12 | 12 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.28% | 1.01% | 1.03% | 1.07% | 1.07% | 1.11% | 1.11% | 1.11% | 1.23% | 1.26% | 1.13% | 1.00% | 1.15% | 1.20% | 1.33% |
Hologic's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.00B, with a low forecast of $1.00B, and a high forecast of $1.00B. HOLX's average Quarter revenue forecast represents a 260.47% increase compared to the company's last Quarter revenue of $277.90M (Dec 23).
Hologic EBITDA Forecast
| Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 6 | 5 | 4 | 8 | 5 | 3 | 3 | 6 | 9 | 8 | 4 | 3 | 3 | 6 | 14 | 12 | 7 | 6 | 6 | 7 | 6 | 7 | 10 | 7 | 12 | 12 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $198.20M | $305.50M | $1.40M | $376.70M | $354.20M | $208.70M | $345.90M | $702.90M | $752.40M | $450.90M | $463.80M | $883.90M | $984.60M | $662.80M | $290.40M |
| Avg Forecast | $442.03M | $450.54M | $439.86M | $437.57M | $426.77M | $432.44M | $425.93M | $422.93M | $406.94M | $410.31M | $403.62M | $399.01M | $378.82M | $387.93M | $600.84M | $383.10M | $364.00M | $371.84M | $546.22M | $560.13M | $314.18M | $329.21M | $496.56M | $434.78M | $380.11M | $378.44M | $907.78M | $511.15M | $408.02M | $224.75M |
| High Forecast | $447.00M | $455.60M | $444.80M | $442.49M | $431.56M | $437.30M | $430.71M | $427.68M | $411.51M | $414.92M | $411.38M | $403.49M | $378.99M | $387.93M | $721.01M | $393.52M | $368.63M | $376.02M | $655.46M | $672.16M | $314.18M | $329.21M | $595.88M | $434.78M | $380.11M | $378.44M | $1.09B | $511.15M | $408.02M | $224.75M |
| Low Forecast | $439.99M | $448.45M | $437.82M | $435.55M | $424.79M | $430.44M | $423.96M | $420.97M | $405.05M | $408.41M | $401.75M | $397.16M | $378.64M | $387.93M | $480.67M | $378.13M | $359.11M | $370.12M | $436.98M | $448.11M | $314.18M | $329.21M | $397.25M | $434.78M | $380.11M | $378.44M | $726.22M | $511.15M | $408.02M | $224.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.52% | 0.84% | 0.00% | 0.69% | 0.63% | 0.66% | 1.05% | 1.42% | 1.73% | 1.19% | 1.23% | 0.97% | 1.93% | 1.62% | 1.29% |
3 analysts predict HOLX's average Quarter EBITDA for Mar 24 to be $600.84M, with a high of $721.01M and a low of $480.67M. This is 203.15% upper than Hologic's previous annual EBITDA (Dec 23) of $198.20M.
Hologic Net Income Forecast
| Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 6 | 5 | 4 | 8 | 5 | 3 | 3 | 6 | 9 | 8 | 4 | 3 | 3 | 6 | 14 | 12 | 7 | 6 | 6 | 7 | 6 | 7 | 10 | 7 | 12 | 12 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $246.50M | $90.60M | $-40.50M | $218.50M | $187.40M | $118.70M | $228.40M | $455.70M | $499.20M | $328.80M | $268.40M | $619.90M | $654.40M | $495.00M | $137.90M |
| Avg Forecast | $307.10M | $320.26M | $308.13M | $286.05M | $282.50M | $282.13M | $274.45M | $265.75M | $258.17M | $260.38M | $251.76M | $240.00M | $239.08M | $240.07M | $389.42M | $224.15M | $198.27M | $209.83M | $354.02M | $370.06M | $147.67M | $168.01M | $321.84M | $313.08M | $237.34M | $264.70M | $627.00M | $512.54M | $290.72M | $91.25M |
| High Forecast | $311.59M | $324.94M | $312.63M | $290.23M | $286.62M | $286.25M | $278.46M | $269.63M | $261.94M | $264.18M | $258.82M | $247.06M | $239.10M | $240.11M | $467.31M | $231.23M | $207.71M | $212.90M | $424.83M | $444.07M | $147.67M | $168.01M | $386.21M | $313.08M | $237.34M | $264.70M | $752.40M | $512.54M | $290.72M | $91.25M |
| Low Forecast | $305.25M | $318.33M | $306.27M | $284.33M | $280.80M | $280.44M | $272.79M | $264.15M | $256.62M | $258.81M | $249.41M | $235.29M | $239.06M | $240.02M | $311.54M | $219.43M | $188.83M | $208.57M | $283.22M | $296.05M | $147.67M | $168.01M | $257.47M | $313.08M | $237.34M | $264.70M | $501.60M | $512.54M | $290.72M | $91.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 0.46% | -0.19% | 0.62% | 0.51% | 0.80% | 1.36% | 1.42% | 1.59% | 1.39% | 1.01% | 0.99% | 1.28% | 1.70% | 1.51% |
Hologic's average Quarter net income forecast for Mar 24 is $389.42M, with a range of $311.54M to $467.31M. HOLX's average Quarter net income forecast represents a 57.98% increase compared to the company's last Quarter net income of $246.50M (Dec 23).
Hologic SG&A Forecast
| Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 6 | 5 | 4 | 8 | 5 | 3 | 3 | 6 | 9 | 8 | 4 | 3 | 3 | 6 | 14 | 12 | 7 | 6 | 6 | 7 | 6 | 7 | 10 | 7 | 12 | 12 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $260.70M | $232.40M | $240.00M | $243.20M | $272.00M | $256.50M | $244.20M | $271.90M | $265.30M | $294.50M | $260.00M | $220.40M | $219.50M | $221.30M | $208.80M |
| Avg Forecast | $252.15M | $257.01M | $250.91M | $249.61M | $243.45M | $246.68M | $242.97M | $241.25M | $232.13M | $234.06M | $230.24M | $227.61M | $216.09M | $221.29M | $232.36M | $218.53M | $207.64M | $212.11M | $211.23M | $196.67M | $193.81M | $203.08M | $192.03M | $268.21M | $234.48M | $233.45M | $222.92M | $315.32M | $251.70M | $138.64M |
| High Forecast | $254.99M | $259.89M | $253.73M | $252.41M | $246.18M | $249.45M | $245.70M | $243.96M | $234.74M | $236.68M | $234.67M | $230.17M | $216.19M | $221.29M | $278.83M | $224.48M | $210.28M | $214.50M | $253.48M | $236.00M | $193.81M | $203.08M | $230.44M | $268.21M | $234.48M | $233.45M | $267.51M | $315.32M | $251.70M | $138.64M |
| Low Forecast | $250.99M | $255.82M | $249.75M | $248.45M | $242.32M | $245.54M | $241.84M | $240.14M | $231.06M | $232.97M | $229.17M | $226.55M | $215.99M | $221.29M | $185.88M | $215.70M | $204.85M | $211.13M | $168.99M | $157.34M | $193.81M | $203.08M | $153.62M | $268.21M | $234.48M | $233.45M | $178.34M | $315.32M | $251.70M | $138.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.19% | 1.12% | 1.13% | 1.15% | 1.38% | 1.32% | 1.20% | 1.42% | 0.99% | 1.26% | 1.11% | 0.99% | 0.70% | 0.88% | 1.51% |
Hologic's average Quarter SG&A projection for Mar 24 is $232.36M, based on 3 Wall Street analysts, with a range of $185.88M to $278.83M. The forecast indicates a -10.87% fall compared to HOLX last annual SG&A of $260.70M (Dec 23).
Hologic EPS Forecast
| Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 6 | 5 | 4 | 8 | 5 | 3 | 3 | 6 | 9 | 8 | 4 | 3 | 3 | 6 | 14 | 12 | 7 | 6 | 6 | 7 | 6 | 7 | 10 | 7 | 12 | 12 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.37 | $-0.16 | $0.88 | $0.76 | $0.47 | $0.91 | $1.81 | $1.97 | $1.29 | $1.05 | $2.40 | $2.53 | $1.90 | $0.53 |
| Avg Forecast | $1.30 | $1.36 | $1.31 | $1.21 | $1.20 | $1.20 | $1.16 | $1.13 | $1.09 | $1.10 | $1.07 | $1.02 | $1.01 | $1.02 | $0.98 | $0.95 | $0.84 | $0.89 | $0.88 | $0.91 | $0.62 | $0.71 | $1.60 | $1.32 | $1.00 | $1.12 | $2.62 | $2.17 | $1.23 | $0.39 |
| High Forecast | $1.32 | $1.38 | $1.32 | $1.23 | $1.21 | $1.21 | $1.18 | $1.14 | $1.11 | $1.12 | $1.10 | $1.05 | $1.01 | $1.02 | $0.98 | $0.98 | $0.88 | $0.90 | $0.89 | $0.92 | $0.62 | $0.71 | $1.60 | $1.32 | $1.00 | $1.12 | $2.62 | $2.17 | $1.23 | $0.39 |
| Low Forecast | $1.29 | $1.35 | $1.30 | $1.20 | $1.19 | $1.19 | $1.16 | $1.12 | $1.09 | $1.10 | $1.06 | $1.00 | $1.01 | $1.02 | $0.98 | $0.93 | $0.80 | $0.88 | $0.87 | $0.91 | $0.62 | $0.71 | $1.60 | $1.32 | $1.00 | $1.12 | $2.62 | $2.17 | $1.23 | $0.39 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.44% | -0.18% | 1.00% | 0.83% | 0.75% | 1.28% | 1.13% | 1.49% | 1.29% | 0.94% | 0.92% | 1.17% | 1.55% | 1.37% |
According to 3 Wall Street analysts, Hologic's projected average Quarter EPS for Mar 24 is $0.98, with a low estimate of $0.98 and a high estimate of $0.98. This represents a 97680.00% increase compared to HOLX previous annual EPS of - (Dec 23).
Hologic Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $99.48 | $298.00 | 199.56% | Buy |
| ANGO | AngioDynamics | $6.88 | $15.00 | 118.02% | Buy |
| TFX | Teleflex | $194.43 | $304.36 | 56.54% | Buy |
| BDX | Becton, Dickinson and Company | $224.10 | $283.27 | 26.40% | Buy |
| HAE | Haemonetics | $88.17 | $108.25 | 22.77% | Buy |
| WST | West Pharmaceutical Services | $307.21 | $345.33 | 12.41% | Buy |
| NVST | Envista | $20.61 | $23.11 | 12.13% | Hold |
| ALC | Alcon | $85.81 | $93.89 | 9.42% | Buy |
| HOLX | Hologic | $78.79 | $80.21 | 1.80% | Buy |
| ICUI | ICU Medical | $169.98 | $172.00 | 1.19% | Buy |
| MMSI | Merit Medical Systems | $103.94 | $100.78 | -3.04% | Buy |
| RMD | ResMed | $239.42 | $219.13 | -8.47% | Hold |
| ATR | AptarGroup | $166.69 | $138.00 | -17.21% | Buy |